The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) gamma-linolenic acid (GLA) and/or the pharmaceutically acceptable deri...

The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) γ-linolenic acid (GLA) and/or the pharmaceutically acceptable de...

PROBLEM TO BE SOLVED: To provide an antidepressant which achieves high therapeutic effect in a shorter period and can be safely used without any adverse effect. SOLUTION: The pharmaceutical composition for treating/preventing depression includes an earthworm dry powder as an active ingredient. For treating/preventing depression the pharmaceutical composition can be used alone or used in combination with one or more antidepressants selected from the group consisting of clomipramine nortriptyline...

The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) ?-linolenic acid (GLA) and/or the pharmaceutically acceptable derivati...

The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) ?-linolenic acid (GLA) and/or the pharmaceutically acceptable derivati...

The R-isomer of the hydroxy metabolite of nefazodone R-hydroxynefazodone is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches panic disorders post traumatic stress disorder and sleep disorders.

The invention relates to the use of 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-4-(2-phenoxyethyl)-2H-124-triazol-3(4H)-one (nefazodone) or a pharmaceutically compatible salt thereof for producing medicaments used in the treatment of Parkinson's disease.

The invention relates to the use of 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-4-(2-phenoxyethyl)-2H-124-triazol-3(4H)-one (nefazodone) or a pharmaceutically compatible salt thereof for producing medicaments used in the treatment of Parkinson's disease.